LEAD PIPELINE PROGRAMS

RPHE-7193: Topical Hair Growth Compound

Androgenetic alopecia or common male pattern baldness (MPB) accounts for more than 95% of hair loss in men. By the age of thirty-five two-thirds of American men will experience some degree of appreciable hair loss and by the age of fifty approximately 85% of men have significantly thinning hair. Approximately twenty five percent of men who suffer with male pattern baldness begin the painful process before they reach the age of twenty-one.

According to American Hair Loss Association and contrary to societal belief, most men who suffer from male pattern baldness are extremely unhappy with their situation and would do anything to change it. Hair loss affects every aspect of the hair loss sufferer's life. It affects interpersonal relationships as well as the professional lives of those suffering from it. It is also not uncommon for men to change their career paths because of their hair loss.

The need for a better hair loss treatment can be considered grave. Rophe Pharma has obtained experimental data from using RPHE-7193 as a topical hair growth compound that is demonstrating promising results in men. The initial results indicate that it may be a more effective topical hair growth compound than Rogaine, a determination which will be confirmed in controlled clinical studies.

Although it has been known for over 30 years that minoxidil (Rogaine) stimulates hair growth, the understanding of its mechanism of action on the hair follicle yet remains extremely limited. There is some evidence that the stimulatory effect of minoxidil on hair growth may be due to the opening of potassium channels by minoxidil sulphate, but this idea to date has been difficult to prove. RPHE-7193 is not a direct potassium channel blocker as minoxidil is, but it is involved in calcium-activated potassium channels by possibly promoting membrane depolarization and enhancing Ca2+ influx, thus it may result in hair growth in a manner similar to minoxidil. In-vitro testing will be conducted and data collected to better understand the precise mechanism of action of RPHE-7193 on hair growth.

The IP includes the use of RPHE-7193 alone or in combination with other drugs for enhanced hair growth effect.